Biogen Analyst Price Targets - Benzinga

Biogen Inc

BIIBNASDAQ

Trade with Public

Trade with Public

$253.62

3.971.59%

마지막 업데이트: Oct 30, 4:06 PM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

© 2026 Benzinga | All Rights Reserved

Biogen Analyst Price Targets

Wall Street analyst price targets and consensus rating for Biogen (BIIB).

Price Target Range — 7 Quarters

Analyst Consensus — 25 Analysts

19Buy

6Hold

Consensus RatingBuy# Analysts25Avg. Consensus PT$244Upside to Avg. PT-3.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 29, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$248→$272
Oct 29, 2026	Argus Research	Jasper Hellweg	Upgrade	Hold→Buy	$280
Oct 29, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$256→$272
Oct 29, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$231→$238
Oct 29, 2026	UBS	Michael Yee	PT Raise	Buy	$270→$300
Oct 29, 2026	TD Cowen	Phil Nadeau	PT Raise	Buy	$250→$260
Oct 29, 2026	Wedbush	Laura Chico	PT Raise	Neutral	$212→$225
Oct 29, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$235→$260
Oct 29, 2026	Baird	Brian Skorney	PT Raise	Outperform	$250→$290
Oct 29, 2026	Needham	Ami Fadia	PT Raise	Buy	$256→$290
Oct 28, 2026	Barclays	Emily Field	PT Raise	Equal-Weight	$200→$230
Oct 22, 2026	B of A Securities	Jason Zemansky	PT Raise	Neutral	$219→$244
Oct 21, 2026	TD Cowen	Phil Nadeau	PT Raise	Buy	$225→$250
Oct 20, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$250→$310
Oct 12, 2026	JP Morgan	Chris Schott	Upgrade	Neutral→Overweight	$210→$300
Oct 9, 2026	UBS	Michael Yee	PT Raise	Buy	$240→$270
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$260→$256
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Reduce	$165→$175
Sep 3, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$225→$245
Aug 25, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$240→$260

Analyst Ratings News

Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday

Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.

Avi Kapoor

PRO
Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $272

Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $248 to $272.

Benzinga Newsdesk

PRO
Argus Research Upgrades Biogen to Buy, Announces $280 Price Target

Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $280 price target.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Biogen, Raises Price Target to $272

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $256 to $272.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $238

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $231 to $238.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Biogen, Raises Price Target to $300

UBS analyst Michael Yee maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $270 to $300.

Benzinga Newsdesk